Rocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is projected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals Stock Up 6.5%

Shares of NASDAQ RCKT opened at $4.25 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.30 and a quick ratio of 7.30. The stock has a market capitalization of $459.94 million, a PE ratio of -1.89 and a beta of 0.48. Rocket Pharmaceuticals has a one year low of $2.19 and a one year high of $10.17. The business’s fifty day moving average price is $3.54 and its 200-day moving average price is $3.41.

Analyst Ratings Changes

RCKT has been the subject of a number of research reports. Morgan Stanley set a $5.00 target price on shares of Rocket Pharmaceuticals in a research report on Thursday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Rocket Pharmaceuticals in a report on Friday, November 7th. JPMorgan Chase & Co. lowered shares of Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Tuesday, November 18th. TD Cowen raised shares of Rocket Pharmaceuticals to a “hold” rating in a report on Friday, December 19th. Finally, Bank of America cut their price target on Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $14.36.

Insiders Place Their Bets

In related news, CEO Gaurav Shah sold 12,279 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the transaction, the chief executive officer directly owned 1,052,045 shares in the company, valued at $3,482,268.95. The trade was a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Martin Wilson sold 12,253 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,557.43. Following the completion of the sale, the general counsel directly owned 683,376 shares in the company, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 29,415 shares of company stock valued at $97,398 over the last 90 days. Company insiders own 24.76% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RCKT. Vanguard Group Inc. lifted its stake in Rocket Pharmaceuticals by 12.6% during the third quarter. Vanguard Group Inc. now owns 6,892,204 shares of the biotechnology company’s stock worth $22,469,000 after purchasing an additional 769,743 shares during the last quarter. MPM Bioimpact LLC raised its holdings in shares of Rocket Pharmaceuticals by 141.2% during the 2nd quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company’s stock valued at $9,563,000 after buying an additional 2,284,816 shares in the last quarter. Millennium Management LLC lifted its position in Rocket Pharmaceuticals by 52.0% in the 3rd quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company’s stock worth $11,639,000 after buying an additional 1,221,554 shares during the last quarter. Newtyn Management LLC boosted its stake in Rocket Pharmaceuticals by 25.1% in the third quarter. Newtyn Management LLC now owns 2,502,863 shares of the biotechnology company’s stock worth $8,159,000 after buying an additional 502,863 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Rocket Pharmaceuticals by 10.7% during the fourth quarter. Geode Capital Management LLC now owns 2,120,269 shares of the biotechnology company’s stock valued at $7,443,000 after acquiring an additional 205,715 shares during the last quarter. Institutional investors own 98.39% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.